( other factors some of which are outsi...)NexMed Announces Completion of Patient Enrollment in Two Pivotal,Phase 3 Studies for Anti-Fungal Product,Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
NexMed Announces Completion of Patient Enrollment in Two Pivotal,Phase 3 Studies for Anti-Fungal Product
other factors, some of which are outside the control of the Company.
Contact
NexMed, Inc.
Linda Burns, 609-371-8123, ext: 184
Senior Director Corporate Relations
lburns@nexmed.com
or
Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
'"/>
Related medicine technology :
1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
Breaking Medicine Technology:Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Limb Sparing Surgery May Offer Little Benefit to Cancer Patients 54221 1Limb Sparing Surgery May Offer Little Benefit to Cancer Patients 54221 2Computer system improves pain therapy for cancer patients 54217 1Computer system improves pain therapy for cancer patients 54217 2Aging with GRACE 3A New health care delivery model improves outcomes saves money 54213 1Aging with GRACE 3A New health care delivery model improves outcomes saves money 54213 2Aging with GRACE 3A New health care delivery model improves outcomes saves money 54213 3
Other Medicine Technology:Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 2Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 3Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 4Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer 2Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer 3Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer 4Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer 5Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer 6
Breaking Medicine News(10 mins):Health News:Depression Survey: Implications for Diverse Communities 2Health News:Depression Survey: Implications for Diverse Communities 3Health News:Luckey & Mullins Joins with Other National Construction Defect Law Firms to Form Chinese Drywall Legal Network 2Health News:SCAN Health Plan Arizona Named one of Area's Best Places to Work by the Phoenix Business Journal and BestCompaniesAZ, LLC 2Health News:Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented 2Health News:Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented 3Health News:Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented 4
[0] Depression Survey: Implications for Diverse Communities [0] Luckey & Mullins Joins with Other National Construction Defect Law Firms to Form Chinese Drywall Legal Network[1] Limited Recall of 120 Cartons of Berries & Balsamic Salad due to Unlabeled Allergen[0] SCAN Health Plan Arizona Named one of Area's Best Places to Work by the Phoenix Business Journal and BestCompaniesAZ, LLC[1] Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented
Other Medicine News:Health News:Millennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare Conference 2Health News:Park Dental Doctor Group Settles Litigation With Service Provider 2Health News:AARP Calls New EEOC Policy 'A Civil Rights and Economic Fiasco' 2Health News:Lower Body Temps Increase Blood Loss During Surgery 2Health News:AspenBio Outlines Steps for FDA 510(k) Clearance of AppyScore(TM), the First Blood-Based Screen/Triage Test for Human Appendicitis 2Health News:AspenBio Outlines Steps for FDA 510(k) Clearance of AppyScore(TM), the First Blood-Based Screen/Triage Test for Human Appendicitis 3Health News:AspenBio Outlines Steps for FDA 510(k) Clearance of AppyScore(TM), the First Blood-Based Screen/Triage Test for Human Appendicitis 4
Millennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare ConferencePark Dental Doctor Group Settles Litigation With Service ProviderAARP Calls New EEOC Policy 'A Civil Rights and Economic Fiasco'AUDIO from Medialink and GlaxoSmithKline: Setting Realistic Goals for a 'New You' in the New YearLower Body Temps Increase Blood Loss During SurgeryAspenBio Outlines Steps for FDA 510(k) Clearance of AppyScore(TM), the First Blood-Based Screen/Triage Test for Human Appendicitis
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |